Influenza virus vaccine quadrivalent, intranasal

Name: Influenza virus vaccine quadrivalent, intranasal

Dosing & Uses

Dosage Forms & Strengths

intranasal suspension

  • 0.2mL (prefilled single use sprayer)

Influenza Prophylaxis

Indicated for prevention of influenza A and B infection in individuals aged 2-49 years

2-49 years: 0.2 mL/dose (0.1 mL/nostril); 1 dose/season

Intranasal administration for age ≥50 years: Safety and efficacy not established

ALERT: ACIP states intranasal flu vaccine should NOT be used for 2016-2017 season

  • June 22, 2016: CDC’s Advisory Committee on Immunization Practices (ACIP) voted that live attenuated influenza vaccine (LAIV), also known as the “nasal spray” flu vaccine, should not be used during the 2016-2017 flu season
  • This ACIP vote is based on data showing poor or relatively lower effectiveness of LAIV from 2013 through 2016
  • In late May 2016, preliminary data on the effectiveness of LAIV among children aged 2-17 yr during 2015-2016 season became available from the U.S. Influenza Vaccine Effectiveness Network
  • That data showed the estimate for LAIV VE among study participants in that age group against any flu virus was 3% (with a 95% Confidence Interval (CI) of -49% to 37%); this 3% estimate means no protective benefit could be measured
  • In comparison, IIV (flu shots) had a VE estimate of 63% (with a 95% CI of 52-72%) against any flu virus among children aged 2-17 yr
  • http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html

Dosing Considerations

Contains the following 4 viral strains for 2016-2017 northern hemisphere season:

A/California/7/2009 (H1N1)-like (same strain as was used for 2009 H1N1 monovalent vaccines)

A/Hong Kong/4801/2014 (H3N2)-like virus (new for 2016-2017)

B/Phuket/3073/2013-like virus (B/Yamagata lineage)

B/Brisbane/60/2008-like (B/Victoria lineage vaccine virus)

Dosage Forms & Strengths

intranasal suspension

  • 0.2mL (prefilled single use sprayer)

Influenza Prophylaxis

Indicated for prevention of influenza A and B infection individuals aged 2-49 years

<2 year: Safety and efficacy not established

2-8 years: 0.2 mL/dose (0.1 mL in each nostril) x1-2 doses/season (see Administration)

≥9 years: As in adults; 0.2 mL/dose (0.1 mL/nostril); 1 dose/season

ALERT: ACIP states intranasal flu vaccine should NOT be used for 2016-2017 season

  • June 22, 2016: CDC’s Advisory Committee on Immunization Practices (ACIP) voted that live attenuated influenza vaccine (LAIV), also known as the “nasal spray” flu vaccine, should not be used during the 2016-2017 flu season
  • This ACIP vote is based on data showing poor or relatively lower effectiveness of LAIV from 2013 through 2016
  • In late May 2016, preliminary data on the effectiveness of LAIV among children aged 2-17 yr during 2015-2016 season became available from the U.S. Influenza Vaccine Effectiveness Network
  • That data showed the estimate for LAIV VE among study participants in that age group against any flu virus was 3% (with a 95% Confidence Interval (CI) of -49% to 37%); this 3% estimate means no protective benefit could be measured
  • In comparison, IIV (flu shots) had a VE estimate of 63% (with a 95% CI of 52-72%) against any flu virus among children aged 2-17 yr
  • http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html

Dosing Considerations

Contains the following 4 viral strains for 2016-2017 northern hemisphere season:

A/California/7/2009 (H1N1)-like (same strain as was used for 2009 H1N1 monovalent vaccines)

A/Hong Kong/4801/2014 (H3N2)-like virus (new for 2016-2017)

B/Phuket/3073/2013-like virus (B/Yamagata lineage)

B/Brisbane/60/2008-like (B/Victoria lineage vaccine virus)

Pharmacology

Mechanism of Action

Vaccine; vaccines convey active immunity via stimulation of production of endogenously produced antibodies

Pharmacokinetics

Onset: Three weeks after vaccination

Duration: 6 months or more

Distribution: Nasal cavity, stomach, brain, and lungs

(web3)